Anterior Uveitis - Pipeline Review, H2 2014

Published: Dec, 2014 | Pages: 47 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Anterior Uveitis - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Anterior Uveitis - Pipeline Review, H2 2014', provides an overview of the Anterior Uveitis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Anterior Uveitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anterior Uveitis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Anterior Uveitis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Anterior Uveitis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Anterior Uveitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Anterior Uveitis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Anterior Uveitis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Anterior Uveitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Anterior Uveitis Overview 6
Therapeutics Development 7
Pipeline Products for Anterior Uveitis - Overview 7
Pipeline Products for Anterior Uveitis - Comparative Analysis 8
Anterior Uveitis - Therapeutics under Development by Companies 9
Anterior Uveitis - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Anterior Uveitis - Products under Development by Companies 13
Anterior Uveitis - Companies Involved in Therapeutics Development 14
EyeGate Pharmaceuticals, Inc. 14
Neuroptis Biotech 15
Virogenomics, Inc. 16
XOMA Corporation 17
Anterior Uveitis - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
dexamethasone acetate - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
gevokizumab - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
NOP-3 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
NS2 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Peptides to Modulate TCR for Uveitis - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Anterior Uveitis - Recent Pipeline Updates 35
Anterior Uveitis - Dormant Projects 42
Anterior Uveitis - Product Development Milestones 43
Featured News & Press Releases 43
Dec 18, 2014: Aldeyra Therapeutics Submits FDA IND Filing for Noninfectious Anterior Uveitis 43
Apr 09, 2013: EyeGate Pharma's EGP-437 Matches Standard-of-care's Response Rate In Phase III Study In Patients With Anterior Uveitis 43
Dec 18, 2012: EyeGate Pharma Enrolls Last Patient In Pivotal Phase III Anterior Uveitis Study Of EGP-437 44
Jan 05, 2012: EyeGate Pharma Initiates Phase III Study Of EGP-437 In Patients With Anterior Uveitis 45
Appendix 46
Methodology 46
Coverage 46
Secondary Research 46
Primary Research 46
Expert Panel Validation 46
Contact Us 47
Disclaimer 47

List of Tables
Number of Products under Development for Anterior Uveitis, H2 2014 7
Number of Products under Development for Anterior Uveitis - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Late Stage Development, H2 2014 10
Comparative Analysis by Clinical Stage Development, H2 2014 11
Comparative Analysis by Early Stage Development, H2 2014 12
Products under Development by Companies, H2 2014 13
Anterior Uveitis - Pipeline by EyeGate Pharmaceuticals, Inc., H2 2014 14
Anterior Uveitis - Pipeline by Neuroptis Biotech, H2 2014 15
Anterior Uveitis - Pipeline by Virogenomics, Inc., H2 2014 16
Anterior Uveitis - Pipeline by XOMA Corporation, H2 2014 17
Assessment by Monotherapy Products, H2 2014 18
Number of Products by Stage and Target, H2 2014 20
Number of Products by Stage and Mechanism of Action, H2 2014 22
Number of Products by Stage and Route of Administration, H2 2014 24
Number of Products by Stage and Molecule Type, H2 2014 26
Anterior Uveitis Therapeutics - Recent Pipeline Updates, H2 2014 35
Anterior Uveitis - Dormant Projects, H2 2014 42